Latest From PharmaMar SA
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.
The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- PharmaMar SA
- Senior Management
José María Fernández Sousa-Faro, PhD, Pres. & CEO
Maria Luisa de Francia Caballero, CFO
- Contact Info
Phone: (34) 91 846 6000
Avda. De los Reyes,1
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.